Electroencephalography-Vigilance Measures in Response to Ketamine Effects in Major Depressive Disorder

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023752%3A_____%2F25%3A43921673" target="_blank" >RIV/00023752:_____/25:43921673 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11120/25:43928962

Výsledek na webu

<a href="https://doi.org/10.1007/978-1-0716-4603-8_13" target="_blank" >https://doi.org/10.1007/978-1-0716-4603-8_13</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/978-1-0716-4603-8_13" target="_blank" >10.1007/978-1-0716-4603-8_13</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Electroencephalography-Vigilance Measures in Response to Ketamine Effects in Major Depressive Disorder

Popis výsledku v původním jazyce

Ketamine is emerging as a treatment for difficult-to-treat depression, with its efficacy linked to EEG measures of alertness. This study by Ip and coworkers (2024) explored how brain arousal responds to intravenous ketamine, quantified through EEG vigilance measures. Two cohorts of 24 depressed patients each were examined. A clinical response was defined as a &gt;33% reduction in Montgomery–Åsberg Depression Rating Scale (MADRS) scores 24 h post-infusion. EEG was recorded pre-, start-, end-, and 24 h post-infusion, and the Vigilance Algorithm Leipzig (VIGALL) assessed EEG stages ranging from high vigilance (A1) to low vigilance (B2/3) and sleep onset (C). Ketamine increased low-vigilance stage B1, correlated with serum ketamine levels but independent of clinical response. Responders exhibited a decrease in high-vigilance A1 and an increase in low-vigilance B2/3, observed in both ketamine and placebo conditions. Pretreatment EEG differed between responders and non-responders, with 53% of responders showing high vigilance A1 compared to 21% of non-responders. Logistic regression predicted outcomes with an AUC of 0.7. Pretreatment EEG vigilance stages, particularly A1, may serve as a predictive biomarker for clinical response to ketamine treatment.

Název v anglickém jazyce

Electroencephalography-Vigilance Measures in Response to Ketamine Effects in Major Depressive Disorder

Popis výsledku anglicky

Ketamine is emerging as a treatment for difficult-to-treat depression, with its efficacy linked to EEG measures of alertness. This study by Ip and coworkers (2024) explored how brain arousal responds to intravenous ketamine, quantified through EEG vigilance measures. Two cohorts of 24 depressed patients each were examined. A clinical response was defined as a &gt;33% reduction in Montgomery–Åsberg Depression Rating Scale (MADRS) scores 24 h post-infusion. EEG was recorded pre-, start-, end-, and 24 h post-infusion, and the Vigilance Algorithm Leipzig (VIGALL) assessed EEG stages ranging from high vigilance (A1) to low vigilance (B2/3) and sleep onset (C). Ketamine increased low-vigilance stage B1, correlated with serum ketamine levels but independent of clinical response. Responders exhibited a decrease in high-vigilance A1 and an increase in low-vigilance B2/3, observed in both ketamine and placebo conditions. Pretreatment EEG differed between responders and non-responders, with 53% of responders showing high vigilance A1 compared to 21% of non-responders. Logistic regression predicted outcomes with an AUC of 0.7. Pretreatment EEG vigilance stages, particularly A1, may serve as a predictive biomarker for clinical response to ketamine treatment.

Druh

C - Kapitola v odborné knize

CEP obor

—

OECD FORD obor

30103 - Neurosciences (including psychophysiology)

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název knihy nebo sborníku

Ketamine. From Neurobiology to Emergency and Anesthesia Care, Volume I

ISBN

978-1-07-164602-1

Počet stran výsledku

17

Strana od-do

279-295

Počet stran knihy

636

Název nakladatele

Humana Press

Místo vydání

New York

Kód UT WoS kapitoly

—